[{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Rona Therapeutics
Rona licensed Sanofi’s siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neuro and muscular disease candidates for ex-China territories.
The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.